Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of about $30 billion, a person familiar with the matter said on Monday. The ...

Becton Dickinson and Co. said it plans to break off its bioscience and diagnostic solutions business to focus on medical technology. Chief Executive Tom Polen said he believes the separation would ...

Activist investor Starboard Value is urging Becton Dickinson to sell its life sciences division, citing potential value gains. Analysts estimate a spin-off could boost the company's worth by up to 30% ...

Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.

BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $269 from $265 and keeps a Buy rating on the shares after ...

Wells Fargo lowered the firm’s price target on Becton Dickinson (BDX) to $270 from $275 and keeps an Overweight rating on the shares. The firm ...